Loading...
LONN logo
LONN
Lonza Group

Vacaville And Visp Facilities Will Secure Future Biologics Demand

Published
02 Feb 25
Updated
01 May 25
AnalystConsensusTarget's Fair Value
CHF 665.36
18.3% undervalued intrinsic discount
04 Sep
CHF 543.80
Loading
1Y
0.5%
7D
-2.6%

Author's Valuation

CHF 665.4

18.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Narrative
Updates8

Shared on01 May 25
Fair value Increased 2.33%

Read more

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on17 Apr 25
Fair value Decreased 0.28%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on09 Apr 25
Fair value Decreased 5.03%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on02 Apr 25
Fair value Increased 1.87%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on12 Mar 25
Fair value Increased 1.25%

AnalystConsensusTarget has increased shares outstanding growth rate from -0.0% to -0.0%.

Read more